14 results about "Vancomycinum" patented technology

This application relates to the field of tumor treatment technology, specifically to a drug combination and evaluation method for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy. The drug combination comprises vancomycin and an immune checkpoint inhibitor. Vancomycin is used to remodel the gut microbiota and reduce L-asparagine levels; the immune checkpoint inhibitor is used to activate CD8. + T-cell anti-tumor response. By combining vancomycin with immune checkpoint inhibitors, the antigen-presenting capacity of dendritic cells is enhanced, thereby increasing the sensitivity of MSS CRC to anti-PD-1 or anti-PD-L1 immunotherapy. This application focuses on the upstream initiation link of gut microbiota-metabolites-dendritic cells-immune activation, relieving the inhibition of dendritic cell antigen presentation by L-asparagine and enhancing CD8+. + T cell activation and tumor immune response enhance the sensitivity of MSS-type colorectal cancer to anti-PD-1 / PD-L1 therapy.

A dynamic antimicrobial hydrogel based on natural receptor-ligand recognition, and a preparation method and use thereof are provided. A ligand vancomycin and a receptor AA-based material each are first modified with a modification material, and then a photoinitiator is added to prepare a hydrogel material under irradiation of ultraviolet (UV) light. In the hydrogel, a three-dimensional (3D) network structure is formed through crosslinking. After undergoing a fracture under an external pressure, the hydrogel can rapidly heal itself through crosslinking due to a ligand-receptor interaction and a multi-hydrogen-bond interaction, which bio-mimicks a natural ligand-receptor interaction to realize the dynamics of the hydrogel material. The high antiomicrobial activity of vancomycin imparts the functionality of the hydrogel material; and the physiologically-derived monomer improves the biocompatibility and reduces the biological toxicity.

This invention discloses a method for isolating and extracting *Havnia vesicularis* using penicillin and vancomycin. The method mainly includes the following steps: inclusion and screening of patients with bipolar disorder; collection and processing of feces from these patients; isolation and treatment of *Havnia vesicularis* by adding penicillin and vancomycin to the feces; and identification of *Havnia vesicularis*. This invention improves the isolation efficiency and success rate of *Havnia vesicularis*, solving the problems of low isolation efficiency and poor identification accuracy in existing technologies.

The application discloses a method for efficiently preparing lignin nanoparticles with a hollow structure and application thereof, and belongs to the technical field of material grading and purification. The method comprises the following steps: lignin is prepared into a nanoparticle suspension through a reverse solvent precipitation method, and the prepared lignin nanoparticle suspension is graded by controlling a centrifugal speed, so that the lignin nanoparticles with the hollow structure are obtained. The method has the advantages of simple operation, short time consumption, high efficiency, green environmental protection, low cost and easy industrial production. Meanwhile, vancomycin can be loaded by adding the vancomycin in a self-assembly process, so that a new idea is provided for high-value utilization of lignin.

The invention relates to the field of biotechnology, medicine and cosmetology, and more particularly to a hybrid matrix for use as a biological graft in the preparation of cardiac prostheses. The technical result of the invention includes improving the surface biocompatibility and the stability and durability of a biological graft which provides an antimicrobial response, and also preventing calcification. A method for producing a hybrid biomatrix comprises the following steps: pre-purifying a base of a biomatrix for 0.75-6 hours in two stages, consisting in the decellularization of xenopericardium in a 2-5 wt% water-alcohol solution of Tween-80, saturated with CO2, at a temperature of 20-400°C and a pressure of 10-30 MPa, and the subsequent decellularization of the xenopericardium in a multi-component system containing a solution based on supercritical CO2 and a 1-1.5 vol% addition of a 2-5 wt% water-alcohol solution of Tween-80, at a temperature of 20-400°C and a pressure of 10-30 MPa; stabilizing the biomatrix base by treatment with a 0.1-0.5 wt% aqueous buffer solution of genipin having a pH of 6.0-7.4 for 3-4 hours; and applying to the pre-purified biomatrix base a coating consisting of an aqueous solution of chitosan nanoparticles with an antimicrobial doping additive in the form of silver or vancomycin nanoparticles in a carbonic acid solution, at a pressure of 20-30 MPa and a temperature of 23-270°C for 1-6 hours.

This utility model provides a vancomycin sample pushing device for a mass spectrometer, belonging to the field of sample pushing technology. It includes a shock-absorbing assembly, comprising a support plate mounted on top of a base plate. A fixing groove is slidably disposed on the top of the support plate, and a slot is formed in the middle of the fixing groove. A lifting block is slidably disposed on the fixing groove through the slot. A first lifting plate is disposed at the bottom of the lifting block, and a telescopic rod is disposed at the bottom of the first lifting plate. A fixing ring is disposed at the bottom of the telescopic rod. The support plate on top of the base plate serves as a base support, and its top-slidably connected fixing groove slides into the lifting block through the middle slot, guiding the vertical movement of the lifting block. The first lifting plate at the bottom of the lifting block bears the load and initially disperses stress. The telescopic rod below absorbs vibration energy using its telescopic characteristics, and the bottom fixing ring limits the range of motion of the telescopic rod and further disperses stress, ultimately achieving effective buffering of vibrations during device operation.

This invention belongs to the field of antibacterial materials, specifically relating to a composite antibacterial material modified with vancomycin through magnetically responsive bond grafting. The material comprises a magnetocaloric material, a polymer coated with the magnetocaloric material having free amino and / or hydroxyl groups, and vancomycin grafted onto the polymer via magnetron sputtering linkage residues. The magnetocaloric material is a functional material capable of generating magnetocaloricity under an alternating magnetic field. The magnetron sputtering linkage residues contain magnetically responsive bonds that can break under an alternating magnetic field, and these magnetically responsive bonds are azo bonds. This invention also provides a method for preparing the material and its applications. This invention has found that the composite material, based on the combined control of the components and modification methods, can unexpectedly achieve synergistic effects, thus effectively improving antibacterial activity and antibacterial spectrum. Furthermore, it can achieve magnetron sputtering of vancomycin, thereby achieving a magnetron sputtering attenuation effect.

The application discloses a vancomycin chemiluminescence immunoassay reagent and a preparation and detection method thereof. The immunoreagent developed by using a high-titer anti-vancomycin specific antibody can accurately determine the content of vancomycin in serum and plasma samples. Compared with traditional methods, the vancomycin chemiluminescence immunoassay reagent provided by the application has high sensitivity and strong specificity, and is combined with a chemiluminescence immunoassay analyzer, and has the advantages of simple operation, high throughput, accurate detection results and the like, and has important significance for guiding clinical rational drug use.

This invention relates to the field of vancomycin pharmacokinetic technology, specifically to the design of a vancomycin clearance prediction scheme based on a VPB ensemble model. This method, based on an ensemble learning strategy, constructs a blending ensemble model to predict vancomycin clearance in adult Chinese patients. First, a variational autoencoder is used to amplify the original sample data to increase data diversity. Then, a particle swarm optimization algorithm is introduced to optimize the parameters of multiple base learners, and the prediction results of the optimized base learners are used as new feature inputs. Finally, a support vector regression machine is used as a meta-learner to integrate and model the above features, forming the final vancomycin clearance prediction model. The VPB model constructed in this invention achieves a determination coefficient R² exceeding 0.9 on both the test and training sets, demonstrating superior prediction accuracy compared to population pharmacokinetic models.

This application relates to compositions and methods for use in vancomycin oral solutions. The invention relates to stable vancomycin hydrochloride powder for use in oral liquid formulations. Methods for using vancomycin oral liquid formulations to treat certain diseases (e.g., Clostridium difficile pseudomembranous colitis and staphylococcal enterocolitis), as well as related kits and products, are also provided herein.

The present invention relates to antibiotic-resistant bacteria, and to the prevention or treatment of infections of drug-resistant pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) and / or vancomycin-resistant Enterococcus (VRE). In particular, the invention relates to the treatment or prevention of colonisation of CRE and / or VRE in the gastrointestinal (GI) tract, before they cause invasive infections, for example in the blood. The invention provides novel formulations, pharmaceutical compositions and methods of using them to prevent or treat CRE and / or VRE infections or intestinal colonisations thereof.

The utility model provides a vancomycin sample rotating platform for mass spectrum detection relates to rotating platform technical field, including fixed frame, still include buffer device, buffer device includes the sliding frame of fixed connection in fixed frame, slidingly connected with transmission block on the sliding frame, slidingly connected with sliding axle on transmission block, sliding axle is fixedly connected with swash plate through transmission link on, the utility model discloses rotating platform high -speed operation produces greater centrifugal force, and centrifugal force can make sample container have the tendency of throwing outwards. At this moment, transmission block drives horizontal pole, vertical rod movement, and the displacement of vertical rod is passed to the placing frame through the series link and universal joint, so that the placing frame drives the clamping frame reverse rotation. The torque generated by this reverse rotation is opposite to the direction of the torque formed by the centrifugal force, thereby achieving torque balance, solving the problem that the sample container will also produce uncontrollable displacement under the action of sudden vibration caused by other equipment in the existing laboratory environment in the background art.

This invention discloses a vancomycin resistance gene multiplex detection system based on real-time fluorescence PCR, aiming to establish a TaqMan probe-based multiplex real-time fluorescence PCR detection method for evaluating five common vancomycin resistance gene subtypes in clinical isolates. vanA、vanB、vanC、vanD and vanM The presence of [a substance] is used to clarify the drug resistance mechanism of the strain and guide precise clinical medication. The detection method established in this invention has superior performance, wherein... vanA and vanM The limit of detection is 10 2 copies / µL, vanB、vanC and vanD 10 3 Copies / µL. No specific amplification was observed in non-target strains, vancomycin-sensitive Enterococcus faecalis, and template-free controls. The coefficients of variation of Ct values ​​for each target strain were <1.0% both intra- and inter-batch. With NGS results as a reference, the overall concordance of this system among 108 clinical isolates was 100.00% (108 / 108).